Reading KLRS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KLRS free→Reading KLRS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KLRS free→QuarterlyIQ Insights · KLRS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 12, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Chief Financial Officer On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the “Company”) of his decision to resign as the Chief Financial Officer of the Company, effective April 14, 2026 (the “Separation Date”). Appointment of Principal Financial Officer As a result of Mr. Gall’s resignation, Brett Hagen, the Compan…
Results of Operations and Financial Condition. On March 17, 2026, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18…
Regulation FD Disclosure. On March 9, 2026, Kalaris Therapeutics, Inc. (the “Company”) made available an updated corporate presentation that it plans to use for upcoming meetings with investors and analysts at The Leerink Partners Global Healthcare Conference and other conferences. The presentation includes updates regarding timelines for reporting data from the Company’s Phase 1b/2 multi-ascending dose clinical trial of TH103 and initiating Phase 3 clinical development of TH103, as well as o…
Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the Shares and the Pre-Funded Warrants is being conducted pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act. The Shares and Pre-Funded Warrants have not been registered under the Securities Act or any state securities laws, and the Shares and Pre-Funded Warrants may not be offered or sold in the United States absent registration with the S…
Other Events. Press Release On December 17, 2025, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cash Runway Based on the Company’s current operating plans, the Company’s management expects that its cash, cash equivalents and short-term investments, together with the anticipated net proceeds from the Private Placement, will be sufficient to fun…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 17, 2025, Kalaris Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 4,200,000 shares of the Company’s common stock, par value $0.0001 per sh…
Other Events. On December 17, 2025, the Company issued a press release announcing initial data from its Phase 1a SAD trial of TH103 in treatment-naïve patients with nAMD. The data demonstrate that TH103’s engineered molecular properties translated into clinically meaningful improvements in vision and retinal anatomy, with early signals suggesting the potential for extended treatment durability. Initial Phase 1a Data Support Molecular Hypothesis with Strong Clinical Activity The Phase 1a trial…
Results of Operations and Financial Condition. On November 12, 2025, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Sec…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 28, 2025, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Matthew Gall as Chief Financial Officer and Treasurer of the Company, effective as of November 3, 2025 (the “Effective Date”). In addition, Mr. Gall will serve as the Company’s principal financial officer. Prior to his appointment as Ch…
Results of Operations and Financial Condition. On August 13, 2025, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18…
Results of Operations and Financial Condition. On May 14, 2025, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 o…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Employment Agreement with Andrew Oxtoby On April 10, 2025, Kalaris Therapeutics, Inc. (the “Company”) entered into an employment agreement (the “Oxtoby Employment Agreement”), with Andrew Oxtoby in connection with his continued employment as President and Chief Executive Officer of the Company. The Oxtoby Employment Agreement supersedes all pre-exi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 3, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”), the Board elected Leone Patterson to serve as a member of the Board, effective immediately. Ms. Patterson will serve as a Class III director with a term expiring at the…
of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.